Position
Optas, LLC in Regeneron Pharmaceuticals, Inc.
Back to the book · All holders of REGN
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark $277$771.88 → $772.64
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 365 | $281.7K | — | — | — | 0.0% |
| Q1 2026 | 362 | $279.7K | $772.64 | $277 | −$2.32K | 0.0% |